No single ticker was named. Biotech ETFs are one way for retail investors to get exposure. Not a recommendation.
Abivax as the most obvious biotech buyout
The bull case argued for Abivax: its unique, post-phase-three ulcerative colitis drug makes it the most obvious acquisition candidate in biotech, with every comparable successful trial leading to a multi-billion dollar buyout.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.